# Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

> **NCT04681729** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 82 (actual)

## Conditions studied

- Cold Urticaria

## Interventions

- **DRUG:** Dupilumab SAR231893
- **DRUG:** Placebo
- **DRUG:** Non sedating H1-antihistamine

## Key facts

- **NCT ID:** NCT04681729
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-10
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-04-20
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04681729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04681729, "Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04681729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*